3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Active not recruiting
4
Recruiting
2
Terminated
1
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Sarcoma
3
Prostatic Neoplasms
3
Stomach Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Thrombosis
1
Stroke
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
Rhabdomyosarcoma
1
Resectable Pancreatic Carcinoma
1
Rectal Neoplasms
1
Pelvic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Nevus, Pigmented
1
Neoplasms
1
Mesothelioma, Malignant
1
Melanoma
1
Liver Neoplasms
1
Liposarcoma
1
Glioma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Desmoplastic Small Round Cell Tumor
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Interventions
Carboplatin
44
Paclitaxel
43
liposomal doxorubicin
23
Topotecan
19
Gemcitabine
18
pembrolizumab
17
Cyclophosphamide
17
Bevacizumab
16
Cisplatin
12
niraparib
9
olaparib
8
fludarabine
7
Taxes
7
Docetaxel
7
aldesleukin
6
Nivolumab
6
Doxorubicin
6
1-dodecylpyridoxal
6
oregovomab
5
fludarabine phosphate
5
Peripheral Blood Stem Cell Transplantation
5
Filgrastim
5
rucaparib
4
durvalumab
4
avelumab
4
Surgical Procedures, Operative
4
Melphalan
4
Ipilimumab
4
Interleukin-2
4
Etoposide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Ovarian Neoplasms
×
X-Rays
×
Clear all
NCT04213794
2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1
Terminated
2 enrolled